Email this page: News Release

FDA Issues Complete Response Letter for XARELTO^® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

^® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome" />

To (email address):   Separate multiple addresses with commas. Maximum 200 characters.
Your name:
Your email address:   Copy yourself These email addresses will be used to email the page on your behalf and will not be used by Johnson & Johnson for any marketing purposes.
Add a comment:
Send:    Full page    Link to page
Type in number:
This helps Johnson & Johnson prevent automated submissions.